Aquestive Therapeutics Inc (NASDAQ:AQST) – Equities researchers at Wedbush lifted their Q3 2019 earnings estimates for Aquestive Therapeutics in a report released on Wednesday, October 16th. Wedbush analyst L. Moussatos now expects that the company will post earnings per share of ($0.82) for the quarter, up from their previous forecast of ($0.84). Wedbush has a “Buy” rating and a $34.00 price objective on the stock. Wedbush also issued estimates for Aquestive Therapeutics’ Q4 2019 earnings at ($0.83) EPS and FY2019 earnings at ($3.06) EPS.
Other equities research analysts have also issued reports about the stock. Zacks Investment Research lowered shares of Aquestive Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, October 8th. ValuEngine raised shares of Aquestive Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. One analyst has rated the stock with a sell rating and six have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $18.46.
Aquestive Therapeutics (NASDAQ:AQST) last posted its earnings results on Tuesday, August 6th. The company reported ($0.82) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.15). Aquestive Therapeutics had a negative return on equity of 8,682.29% and a negative net margin of 119.15%. The business had revenue of $11.13 million for the quarter, compared to the consensus estimate of $10.46 million.
In other news, Director James S. Scibetta purchased 22,971 shares of the company’s stock in a transaction dated Wednesday, August 21st. The shares were purchased at an average price of $3.79 per share, for a total transaction of $87,060.09. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders bought a total of 27,871 shares of company stock worth $121,453 in the last 90 days. Corporate insiders own 55.60% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. lifted its position in shares of Aquestive Therapeutics by 728.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 22,761 shares of the company’s stock worth $93,000 after purchasing an additional 20,014 shares during the period. Canada Pension Plan Investment Board acquired a new position in shares of Aquestive Therapeutics in the 2nd quarter worth approximately $105,000. Wedbush Securities Inc. acquired a new position in shares of Aquestive Therapeutics in the 2nd quarter worth approximately $297,000. Jacobs Levy Equity Management Inc. acquired a new position in shares of Aquestive Therapeutics in the 2nd quarter worth approximately $361,000. Finally, Jane Street Group LLC acquired a new position in shares of Aquestive Therapeutics in the 2nd quarter worth approximately $133,000. Hedge funds and other institutional investors own 66.41% of the company’s stock.
Aquestive Therapeutics Company Profile
Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally.
Further Reading: What are convertible shares?
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.